Profil Financier
Park Soon-jae occupe actuellement le rang #1606 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $2.6 B (+$424 sur 24h).
Park Soon-jae is cofounder and CEO of South Korean biotechnology company Alteogen, which focuses on biosimilars and bio-betters.
Alteogen is known for its ALT-B4, an enzyme with technology that allows drugs to be administered subcutaneously instead of intravenously.
In 2024, Alteogen revealed Merck had agreed to a licensing deal to use ALT-B4 for the drug giant's cancer drug pembrolizumab. Alteogen shares soared 25% in a day following the announcement.
Park's wife, Chung Hye-shin, served as the company's chief strategy officer until 2023.
Prior to cofounding Alteogen in 2008, Park worked at LG Life Sciences and Hanwha Petrochemical, and was a postdoctoral researcher at MIT.